Skip to main content
. Author manuscript; available in PMC: 2011 May 7.
Published in final edited form as: Vaccine. 2010 Mar 21;28(21):3696–3705. doi: 10.1016/j.vaccine.2010.03.016

Figure 3. Uptake of FITC-OVA by BMDC is not enhanced by treatment with CTB.

Figure 3

BMDC treated for 10 min at either 37°C with PBS (untreated), 1 μg/ml of LPS, 1 μg/ml of Pam3CSK, 5 μg/ml of LT-IIa-B5, or 5 μg/ml of CTB were incubated with FITC-OVA (0.2 mg/ml) for 10 min, washed with PBS, and stained with an APC-conjugated anti-CD11c mAb. FITC fluorescence of CD11c-positive, 7-AAD-negative cells was measured by flow cytometry. Data are presented as the MFI. Error bars denote one standard deviation from the mean obtained from triplicate cultures. Key: **, statistical difference from the control at P<0.01; ***, statistical difference from the control at P<0.001; ns, no statistical difference from the control.